ArticleMaterials today. Bio2025
Biomimetic "Trojan Horse" delivery of traditional Chinese medicine with immunogenic hybrid vesicles of bacterial outer membrane and tumor cell membrane for synergistic chemo-immunotherapy of liver cancers.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Angiopep-2-decorated bacterial outer membrane vesicles penetrate the blood-brain barrier for glioblastoma chemo-immunotherapy.Drug delivery · 2026Article
- Therapeutic potential of glycyrrhizic acid in inflammation-related diseases: from HMGB1-oriented molecular insights to preclinical application.Archives of pharmacal research · 2026Review
- Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Advances in Drug Delivery Systems Utilizing Glycyrrhizic Acid and Its Aglycone Glycyrrhetinic Acid in Cancer Therapy.International journal of nanomedicine · 2026Review
- Harmonizing yin and yang, remodeling the microenvironment: the adjuvant potential of Chinese herbal medicine in tumor immunotherapy.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nowadays it is a big challenge to treat liver cancer, owing to the lack of efficient therapeutic paradigms. Currently, the first-line chemotherapy and immunotherapy often suffer from drug resistance, and severe side effects. The emerging Chinese medicine of Glycyrrhizic acid (GA) shows promise for liver cancer therapy, but often exhibits substantial toxicity and side effects. To explore efficient liver cancer treatment paradigms, herein, a "Trojan Horse" strategy is developed using biomimetic nanoplatform to deliver GA for dual chemo-immunotherapy of liver cancer. The nanoplatform (GANPs@COP) is composed of PLGA-coated GANP (GANPs@P) as the core, and hybrid vesicle (CO) of tumor cell membranes (CMVs) and bacterial outer membranes (OMVs) as the shell. In the nanoplatform, CMVs and OMVs contribute to tumor targeting and immunogenicity, respectively, while GA executes chemotherapy to locally destruct primary tumor cells. The nanoplatform synergistically ablate tumors by modulating tumor immunosuppressive microenvironment, promoting secretion of inflammatory cytokines, repolarizing macrophage M2 to M1, maturating dendritic cells, and eliciting CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.